Harvoni (ledipasvir/sofosbuvir)
contains a HCV NS5A inhibitor
(ledipasvir) and a nucleotide
inhibitor of HCV NS5B
RNA‑dependent RNA polymerase
(sofosbuvir). Harvoni is indicated
for the treatment of chronic
hepatitis C (CHC) genotype 1
infection in adults. Harvoni should
not be administered concurrently
with other medicinal products
containing any of the same active
components. Harvoni is available
as a fixed dose combination tablet
containing 90 mg of ledipasvir and
400 mg of sofosbuvir. Harvoni is
available as a bottle of 28 tablets.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 15
BREAST Cancer Network Australia (BCNA) has welcomed a PBAC recommendation to subsidise the breast cancer drug Enhertu (trastuzumab deruxtecan) for HER2-low metastatic breast cancer on the PBS.
PHARMACY Connect (PC2024) has revealed that Olympian Peter Bol will be sharing his journey from adversity to athletic greatness at the conference in Sep in Sydney.
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.